<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-BAI25115-T2D-HN-D0J">
    <metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S1954 IS: Biosimilar Red Tape Elimination Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-06-04</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
        <distribution-code>II</distribution-code>
        <congress>119th CONGRESS</congress>
        <session>1st Session</session>
        <legis-num>S. 1954</legis-num>
        <current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
        <action>
            <action-date date="20250604">June 4, 2025</action-date>
            <action-desc><sponsor name-id="S346">Mr. Lee</sponsor> (for himself, <cosponsor name-id="S409">Mr. Luján</cosponsor>, <cosponsor name-id="S348">Mr.
                    Paul</cosponsor>, and <cosponsor name-id="S388">Ms. Hassan</cosponsor>)
                introduced the following bill; which was read twice and referred to the
                    <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and
                    Pensions</committee-name></action-desc>
        </action>
        <legis-type>A BILL</legis-type>
        <official-title>To improve the requirements for making a determination of interchangeability
            of a biological product and its reference product.</official-title>
    </form>
    <legis-body>
        <section section-type="section-one" id="id86FA91A307794378AEF4A870B9F6AFD6">
            <enum>1.</enum>
            <header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Biosimilar Red Tape Elimination Act</short-title></quote>.</text>
        </section>
        <section id="idA8E53224DCA54B018D53698742C37253">
            <enum>2.</enum>
            <header>Biosimilar biological products</header>
            <subsection id="id79CAACA706BB4872B8195B465CD6EB83">
                <enum>(a)</enum>
                <header>In general</header>
 <text display-inline="yes-display-inline">Section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) is amended—</text>
                <paragraph id="id4D16425366E84EDE9DF39E749589FD24">
                    <enum>(1)</enum>
 <text>in the subsection heading, by striking <quote><header-in-text level="subsection" style="OLC">or interchangeable</header-in-text></quote>;</text>
                </paragraph>
                <paragraph id="idDBA6D26B8937457AAED07ECD2284DF14">
                    <enum>(2)</enum>
 <text>in paragraph (2)—</text> <subparagraph id="id1F1AAFDAE19147399552298D1146C257"> <enum>(A)</enum> <text>by striking subparagraph (B);</text>
                    </subparagraph>
                    <subparagraph id="idF487AD2D4B8D42E1B9D9560ACC2CB034">
                        <enum>(B)</enum>
 <text>by redesignating clauses (ii) and (iii) of subparagraph (A) as subparagraphs (B) and (C), respectively, and adjusting the margins accordingly;</text>
                    </subparagraph>
                    <subparagraph id="id310F5DD803C7487E9DF05FF0EEEC1158">
                        <enum>(C)</enum>
 <text>in subparagraph (A)—</text> <clause id="id6B53EC8C25C3497A96A1FF73B5E0972B"> <enum>(i)</enum> <text>in clause (i), by redesignating subclauses (I) through (V) as clauses (i) through (v), respectively, and adjusting the margins accordingly;</text>
                        </clause>
                        <clause id="idD6AC4F678CF54C8CAB37B71356D18265">
                            <enum>(ii)</enum>
 <text>in clause (i), as so redesignated by clause (i) of this subparagraph, by redesignating items (aa) through (cc) as subclauses (I) through (III), respectively, and adjusting the margins accordingly; and</text>
                        </clause>
                        <clause id="idDC55FA5912774DB98BD20A9C475D9EBB">
                            <enum>(iii)</enum>
 <text>by striking <quote><header-in-text level="subparagraph" style="OLC">(A) In General</header-in-text></quote> and all that follows through <quote>An application submitted under this subsection shall include information</quote> and inserting the following:</text>
                            <quoted-block style="OLC" display-inline="no-display-inline" id="idAA203E6AE5124EF98CA6D66590841A3E">
                                <subparagraph id="idB6B6DF64A76D45F1918B3015CA225C76">
                                    <enum>(A)</enum>
                                    <header>In general</header>
 <text>An application submitted under this subsection shall include information</text>
                                </subparagraph>
                                <after-quoted-block>; </after-quoted-block>
                            </quoted-block>
                        </clause>
                    </subparagraph>
                    <subparagraph id="idE1530BA0EDA24D8EB9F119EE13B48746">
                        <enum>(D)</enum>
 <text>in subparagraph (B), as so redesignated by subparagraph (B) of this paragraph, by striking <quote>clause (i)(I)</quote> and inserting <quote>subparagraph (A)(i)</quote>; and</text>
                    </subparagraph>
                    <subparagraph id="id03E8571B1C654C09991823701B0405D6">
                        <enum>(E)</enum>
 <text>in subparagraph (C), as so redesignated by subparagraph (B) of this paragraph, by redesignating subclauses (I) through (III) as clauses (i) through (iii), respectively, and by adjusting the margins accordingly;</text>
                    </subparagraph>
                </paragraph>
                <paragraph id="id56783C05C14D4D70BFBD64FA0E0191B6">
                    <enum>(3)</enum>
 <text>by amending subparagraph (A) of paragraph (3) to read as follows:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="idFEB8566125E34A779B7CA91A4E4002D5"> <subparagraph id="idf8d9d2cb53014e34a1b505770d202da1"> <enum>(A)</enum> <text>the Secretary determines that the information submitted in the application (or the supplement) is sufficient to show that the biological product is biosimilar to the reference product; and</text>
                        </subparagraph>
                        <after-quoted-block>; </after-quoted-block>
                    </quoted-block>
                </paragraph>
                <paragraph commented="no" display-inline="no-display-inline" id="idef1a3f02077c44ce8ea253e0d95ccaf8">
                    <enum>(4)</enum>
 <text display-inline="yes-display-inline">by amending paragraph (4) to read as follows:</text>
                    <quoted-block style="OLC" display-inline="no-display-inline" id="idE50F84385D3B48B58DBD666CFE10E671">
                        <paragraph id="id310126CD8E5F408982D6ABD07A1F8FA8">
                            <enum>(4)</enum>
                            <header>Interchangeability</header>
                            <subparagraph commented="no" display-inline="no-display-inline" id="ida23a358f2448432592d673bfd300ba35">
                                <enum>(A)</enum>
                                <header>In general</header>
 <text display-inline="yes-display-inline">A biological product licensed under this subsection shall be deemed to be interchangeable with the reference product, subject to subparagraph (B).</text>
                            </subparagraph>
                            <subparagraph commented="no" display-inline="no-display-inline" id="idd08bf50faef34bfd9437d71979d32a39">
                                <enum>(B)</enum>
                                <header>Timing of deemed interchangeability</header>
                                <clause commented="no" display-inline="no-display-inline" id="idae6e2b661a394712bed97811fcf85201">
                                    <enum>(i)</enum>
                                    <header>Licensure on or after transition date</header>
 <text display-inline="yes-display-inline">A biological product licensed under this subsection on or after the transition date described in subparagraph (C) (referred to in this clause as the <quote>applicable biological product</quote>) shall be deemed to be interchangeable with the reference product upon such licensure, unless the applicable biological product relied on the same reference product as another biological product for which—</text>
                                    <subclause commented="no" display-inline="no-display-inline" id="id4757f84938fd4b1ba487e9a13ff87e01">
                                        <enum>(I)</enum>
 <text display-inline="yes-display-inline">licensure under this subsection was in effect on the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>; and</text>
                                    </subclause>
                                    <subclause commented="no" display-inline="no-display-inline" id="id40947c9f9e5f4153826c91084efb68df">
                                        <enum>(II)</enum>
 <text display-inline="yes-display-inline">a first interchangeable exclusivity period under paragraph (6) (as in effect on the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>) is in effect on the date of licensure of the applicable biological product,</text>
                                    </subclause>
                                    <continuation-text continuation-text-level="clause">in which
                                        case the applicable biological product shall be deemed
                                        interchangeable with the reference product under this
                                        paragraph on the date on which the exclusivity period
                                        described in subclause (II) ends.</continuation-text>
                                </clause>
                                <clause commented="no" display-inline="no-display-inline" id="id0e31fea2d52c4d43b386df1936ab8380">
                                    <enum>(ii)</enum>
                                    <header>Licensure prior to transition date</header>
 <text display-inline="yes-display-inline">A biological product licensed under this subsection prior to the transition date described in subparagraph (C) (referred to in this clause as the <quote>applicable biological product</quote>) shall be deemed to be interchangeable with the reference product on such transition date, unless the applicable biological product relied on the same reference product as another biological product for which—</text>
                                    <subclause commented="no" display-inline="no-display-inline" id="id9CD9987E94384D31BE1CA1A3A737451A">
                                        <enum>(I)</enum>
 <text display-inline="yes-display-inline">licensure under this subsection was in effect on the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>; and</text>
                                    </subclause>
                                    <subclause commented="no" display-inline="no-display-inline" id="id54946E5425EA4FCA9E6D66568EEF22E0">
                                        <enum>(II)</enum>
 <text display-inline="yes-display-inline">a first interchangeable exclusivity period under paragraph (6) (as in effect on the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>) is in effect on the transition date,</text>
                                    </subclause>
                                    <continuation-text continuation-text-level="clause">in which
                                        case the applicable biological product shall be deemed
                                        interchangeable with the reference product under this
                                        paragraph on the date on which the exclusivity period
                                        described in subclause (II)
                                        ends.</continuation-text>
                                </clause>
                            </subparagraph>
                            <subparagraph commented="no" display-inline="no-display-inline" id="idea68fdec9388467fae7611556bdbbafe">
                                <enum>(C)</enum>
                                <header>Transition date</header>
 <text display-inline="yes-display-inline">The transition date described in this subparagraph is the date that is 60 days after the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>.</text>
                            </subparagraph>
                        </paragraph>
                        <after-quoted-block>;</after-quoted-block>
                    </quoted-block>
                </paragraph>
                <paragraph id="id3A2E1F76ACCD4906888D42E024F0A182">
                    <enum>(5)</enum>
 <text>by amending paragraph (6) to read as follows:</text> <quoted-block style="OLC" display-inline="no-display-inline" id="idBF2BBBD4B1684C7AAECBF7A6C4B5DC14"> <paragraph id="idc97e6c864c534f49a5ca5ff43502d39e"> <enum>(6)</enum> <header>Transition with respect to preserving first interchangeability exclusivity with respect to certain biological products</header> <text>With respect to a biological product licensed under this subsection before the date of enactment of the <short-title>Biosimilar Red Tape Elimination Act</short-title>, for which there was an unexpired period of first interchangeable exclusivity under this subsection (as then in effect), such unexpired exclusivity period shall remain in effect for the duration of such period.</text>
                        </paragraph>
                        <after-quoted-block>; and</after-quoted-block>
                    </quoted-block>
                </paragraph>
                <paragraph id="idC336D9F817824C5B94A51EB13D081D4C">
                    <enum>(6)</enum>
 <text>in paragraph (8)(D)—</text> <subparagraph id="id5F1B3BB406B64EAEAD3C3E022D3679CA"> <enum>(A)</enum> <text>in clause (i), by striking <quote>class; and</quote> and inserting <quote>class.</quote>;</text>
                    </subparagraph>
                    <subparagraph id="id3C62B703CA584336B876340C349EFA82">
                        <enum>(B)</enum>
 <text>by striking clause (ii); and</text> </subparagraph> <subparagraph id="id457CA168CC0D4AEC817A10BF719FE6E0"> <enum>(C)</enum> <text>by striking <quote>description of—</quote> and all that follows through <quote>criteria that the Secretary</quote> and inserting <quote>description of the criteria that the Secretary</quote>.</text>
                    </subparagraph>
                </paragraph>
            </subsection>
            <subsection id="id961950BE546646C087186687559DE885">
                <enum>(b)</enum>
                <header>Conforming amendments</header>
                <paragraph id="id0D89A4D77F964AA9BEB66947EEA1F2C7">
                    <enum>(1)</enum>
 <text>Section 351(i)(3) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)(3)</external-xref>) is amended by striking <quote>that is shown to meet the standards described in subsection (k)(4)</quote> and inserting <quote>licensed under subsection (k)</quote>.</text>
                </paragraph>
                <paragraph id="idBE01C4D66E964A9487CC775BE89128F6">
                    <enum>(2)</enum>
 <text>Section 352A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/263-1">42 U.S.C. 263–1</external-xref>) is amended by striking <quote>and interchangeable biosimilar biological products</quote> each place it appears.</text>
                </paragraph>
                <paragraph id="idD6979B0220BA44CEB4BCB6F14F38F272">
                    <enum>(3)</enum>
 <text>Section 744G(14) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-51">21 U.S.C. 379j–51(14)</external-xref>) is amended by striking <quote>, including a supplement requesting that the Secretary determine that the biosimilar biological product meets the standards for interchangeability described in section 351(k)(4) of the Public Health Service Act</quote>.</text>
                </paragraph>
                <paragraph id="id70945B068A004BBABC317C1CD501D636">
                    <enum>(4)</enum>
 <text>By amending subsection (l) of section 505B of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355c">21 U.S.C. 355c</external-xref>) to read as follows:</text>
                    <quoted-block style="OLC" display-inline="no-display-inline" id="id3A52C39799BD4DBB98276B6FD99CE5F8">
                        <subsection commented="no" id="idDB0BEFA5E50E4274949D341EAE303DC8">
                            <enum>(l)</enum>
                            <header>Biosimilar biological products</header>
 <text>A biological product for which an application is submitted under section 351(k) of the Public Health Service Act shall not be considered to have a new active ingredient for purposes of this section, unless the application seeks licensure for—</text>
                            <paragraph commented="no" display-inline="no-display-inline" id="id2c585f6b1e9942f7b68422d80001a7d8">
                                <enum>(1)</enum>
 <text display-inline="yes-display-inline">a claimed indication that has been approved for the reference product in a relevant pediatric population or for which there is a deferral of the pediatric assessment under paragraph (4) for the reference product; and </text>
                            </paragraph>
                            <paragraph commented="no" display-inline="no-display-inline" id="idbc0b5d736b2948f9a79ef77e107fa709">
                                <enum>(2)</enum>
 <text display-inline="yes-display-inline">the assessment would not involve the development of a biological product with a strength, dosage form, route of administration, or condition of use that could not be licensed under section 351(k) of the Public Health Service Act.</text>
                            </paragraph>
                        </subsection>
                        <after-quoted-block>. </after-quoted-block>
                    </quoted-block>
                </paragraph>
            </subsection>
            <subsection id="idac7aa1cc7d2e4efda023695e4cf9d9ab">
                <enum>(c)</enum>
                <header>Guidance</header>
 <text>The Secretary shall—</text> <paragraph id="idb0899f0a147d4b40b76497a596e076a9"> <enum>(1)</enum> <text>not later than 18 months after the date of enactment of this Act, update existing draft and final guidance to reflect the amendments made by this Act, including by revising or revoking the guidance document titled <quote>Considerations in Demonstrating Interchangeability With a Reference Product</quote> (May 2019) and <quote>Considerations in Demonstrating Interchangeability With a Reference Product: Update</quote> (June 2024);</text>
                </paragraph>
                <paragraph id="id7d2ed0c703384ae784a9b9180a1ecb02">
                    <enum>(2)</enum>
 <text>not later than 18 months after the date of enactment of this Act, issue or revise guidance on review and approval of biosimilar biological products under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>) relating to the data and information that an applicant is required to submit to support a determination that a biosimilar biological product that is the subject of an application under such section is biosimilar to the reference product (as defined in section 351(i) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>)); and</text>
                </paragraph>
                <paragraph id="idc4160b84f00b4f228011e604266d893c" commented="no" display-inline="no-display-inline">
                    <enum>(3)</enum>
 <text>not later than 18 months after the comment period closes on the guidance under paragraphs (1) and (2), issue revised draft or final versions of such guidances.</text>
                </paragraph>
            </subsection>
        </section>
    </legis-body>
</bill>

